Hengrui Pharma strengthens its oncology portfolio as 64 abstracts, including key proffered papers on HER2 and HER3 antibody-drug conjugates, are accepted for presentation at ESMO 2026.
Hengrui Pharma has secured 64 accepted abstracts for the ESMO 2026 conference, highlighting a robust R&D pipeline that spans over ten distinct oncology and supportive care areas. The inclusion of three 'Proffered Papers' and three 'Rapid-Oral' presentations underscores the high clinical significance of their current research, particularly regarding their focus on HER2 and HER3-specific antibody-drug conjugates (ADCs).
Hengrui Pharma had 64 abstracts accepted for the conference.
The studies cover over ten areas of oncology and supportive care, with a specific emphasis on HER2 and HER3-specific antibody-drug conjugates.
Jiangsu Hengrui Pharmaceuticals announced that 64 of its research abstracts have been accepted for the upcoming ESMO 2026 congress. The selection includes three proffered papers and three rapid-oral presentations, highlighting the company's robust clinical progress across ten oncology therapeutic areas, with a specific focus on HER2 and HER3 antibody-drug conjugates.
The acceptance of 64 abstracts, including high-profile proffered papers, serves as a clinical catalyst that validates the company's oncology pipeline and its competitive position in antibody-drug conjugate development.